OPmobility Reports Q1 Revenue Dip Amid Automotive Industry Slowdown 
LG Innotek Stock Hits Record High on $68M Automotive Wi-Fi 7 Deal 
Nidec Stock Rises After Accounting Probe Report Eases Delisting Concerns 
Rising Jet Fuel Costs from Iran Conflict Push Airfare Higher Across Europe 
Want to cut your energy bills? Here’s how five experts are doing it 
Huawei Expands Vietnam Presence Through Strategic Partnership with SHB Bank 
NVIDIA Acquisition Rumors Dismissed by Morgan Stanley as Strategically Flawed 
Samsung Boosts DRAM Supply to Tesla as AI-Driven Memory Demand Surges 
SK Hynix Launches 192GB SOCAMM2 Memory for Nvidia’s Next-Gen AI Chips 
J.P. Morgan Downgrades Essity AB on Rising Costs and Weak Earnings Outlook 
Indian Refiners Use Yuan via ICICI Bank to Pay for Iranian Oil Under U.S. Sanctions Waiver 
SK Hynix to Invest $13 Billion in AI Chip Packaging Facility 
Jeff Bezos Eyes $10 Billion Funding Round for AI Venture Project Prometheus 
China Food Delivery Stocks Dip as Regulators Crack Down on “Ghost Deliveries” 
Indonesia and Toyota Explore $300M Bioethanol Investment to Boost Renewable Energy Goals 
Tesla Q1 Earnings Preview: Robotaxi Delays and SpaceX Merger Speculation Grow 
JAPEX Shares Drop as Middle East Tensions Drive LNG Costs and Production Risks 
LEXINGTON, Mass., May 25, 2017 -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective therapeutics for the treatment of cancer, today announced the presentation of a poster describing the Phase 1 trial of CA-170, an oral small molecule dual inhibitor of immune checkpoints PD-1 and VISTA, in the treatment of patients with advanced solid tumors or lymphomas at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting. The meeting will take place from June 2-6 in Chicago.
In addition, researchers from the Dana-Farber Cancer Institute and Boston Children’s Hospital will be presenting information on an investigator-initiated Phase 1 multicenter trial using CUDC-907, Curis’ proprietary drug candidate, to treat children and young adults with relapsed or refractory solid tumors, CNS tumors and lymphoma.
Additional information on the presentations can be found below and can be accessed at www.am.asco.org.
CA-170 Poster Presentation:
| Date/Time: | Monday, June 5, 8 AM — 11:30 AM CDT |
| Abstract Number: | TPS3099 |
| Presentation Title: | Phase 1 trial of CA-170, a novel oral small molecule dual inhibitor of immune checkpoints PD-1 and VISTA, in patients (pts) with advanced solid tumor or lymphomas |
CUDC-907 Poster Presentation:
| Date/Time: | Sunday, June 4, 8 AM — 11:30 AM CDT |
| Abstract Number: | TPS10576 |
| Presentation Title: | Phase 1 multicenter trial of CUDC-907 in children and young adults with relapsed or refractory solid tumors, CNS tumors, and lymphoma |
About Curis
Curis is a biotechnology company focused on the development and commercialization of innovative and effective drug candidates for the treatment of human cancers, including its lead development candidate, CUDC-907, which is being investigated in clinical studies in patients with lymphomas and solid tumors. Curis is also engaged in a broad collaboration with Aurigene in the areas of immuno-oncology and precision oncology. As part of this collaboration, Curis has exclusive licenses to oral small molecule antagonists of the PD1 and VISTA pathways, including PDL1/VISTA antagonist CA-170, and oral small molecule antagonists of the PD1 and TIM3 pathways, including PDL1/TIM3 antagonist CA-327, as well as to molecules designed to inhibit the IRAK4 kinase, including CA-4948. CA-170 is currently undergoing testing in a Phase 1 trial in patients with advanced solid tumors and lymphomas. Curis is also party to a collaboration with Genentech, a member of the Roche Group, under which Genentech and Roche are commercializing Erivedge® for the treatment of advanced basal cell carcinoma, and are further developing Erivedge in other diseases including idiopathic pulmonary fibrosis and myelofibrosis. For more information, visit Curis's website at www.curis.com.
For More Information: James E. Dentzer Chief Financial Officer & Chief Administrative Officer Curis, Inc. 617-503-6500 [email protected] Media Contact David Schull Russo Partners (212) 845-4271 [email protected]
